Seaside granted patent for autism treatment method

A U.S. patent for the method to improve the social and communication functions in autism was granted to Seaside Therapeutics, inc., the company announced today. the United States Patent and Trademark Office (USPTO) granted patent 8,143,311, titled “Methods of Treating Fragile X Syndrome and Autism,” which covers the use of Seaside’s lead product, STX209. the drug candidate is an oral selective gamma-aminobutyric acid-B (GABA-B) receptor agonist currently being studied in a Phase 2b study in autism spectrum disorders and two Phase 3 studies in fragile X syndrome, the most common cause of autism. “We believe STX209 has the potential to improve social function, which represents a new paradigm in the treatment of autism spectrum disorders and fragile X syndrome, and are truly excited about the prospect of helping patients and their families achieve an improved quality of life,” said Randy Carpenter, president and CEO of Seaside in a written statement. according to the company, recent studies show a deficient inhibitory neurotransmission in autism and fragile X syndrome, and STX209 has the potential to normalize this deficiency. Last June, the company announced the beginning of Phase 3 trials of STX209.

In February, 2010, Seaside was issued a patent for a method of treating autism by blocking a certain receptor, the latest in several of the company’s related patents issued in the U.S., Europe and Canada. There is currently no approved drug for the treatment of Fragile X Syndrome, which affects 90,000 Americans, according to the company. Drugs currently in use focus on treating specific symptoms of autism such as anxiety, or improving and controlling behavior.

Seaside granted patent for autism treatment method


Related Websites

    Be Sociable, Share!